

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Sällberg, et al.
Appl. No.	:	10/719,619
Filed	:	November 20, 2003
For	:	VACCINES CONTAINING RIBAVIRIN AND METHOD OF USE THEREOF
Examiner	:	Li, Bao Q.
Group Art Unit	:	1648

INTERVIEW SUMMARY**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

The attached interview summary reflects the substance of the personal interview held between Examiner Li, Supervisor Campell, Quality Assurance Supervisor Yvonne Eyler and the undersigned on January 29, 2007.

Appl. No. : 10/719,619
Filed : November 20, 2003

REMARKS


The undersigned wishes to thank Examiner Li, Supervisor Campell and Quality Assurance Supervisor Yvonne Eyler for the courtesy extended to him during a personal interview on January 29, 2007. During the interview between the undersigned, Examiner Li, Supervisor Campell and Quality Assurance Supervisor Yvonne Eyler, the enablement rejections under 35 U.S.C. § 112, first paragraph raised in the Office Action mailed September 14, 2006 were discussed. The undersigned and the Examiner agreed that Applicants would file an Amendment and Response to the outstanding Office Action that addressed how the claimed methods differ from methods of daily administration of ribavirin in combination with a hepatitis viral antigen.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: March 13, 2007

By: 
Eric S. Furman
Registration No.
Attorney of Record
Customer No. 20,995
(619) 235-8550

3434802
021607